CASI Pharmaceuticals Secures USD 15 Million in PIPE Transaction for Anti-CD38 Monoclonal Antibody Development
CASI Pharmaceuticals (NASDAQ: CASI), a biopharmaceutical company based in China, has announced the signing of...
CASI Pharmaceuticals
CASI Pharmaceuticals Reports Q3 2023 Results with Mixed Fortunes and Positive Developments
China-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has unveiled its financial results for the third quarter...
CASI Pharmaceuticals Enters Assignment Agreement with Mundipharma for Folotyn Commercialization in China
US-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has announced the execution of an assignment agreement with...
CASI Pharmaceuticals Invests in Precision Immune Therapeutics for CID-103 Development
US-based CASI Pharmaceuticals Inc. (NASDAQ: CASI) announced the completion of a financing round for China’s...
Beijing Tianshi Tongda Raises RMB 140M for Autoimmune Disease Therapies
China-based Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd has reportedly raised RMB 140 million (USD...